Displaying drugs 176 - 191 of 191 in total
Hu-rhEGF-rP64k/Mont
Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated for the treatment of advanced non-small cell lung cancer (NSCLC).
Investigational
Matched Description: … Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically ... conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated for the …
XmAb 2513
XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma.
Investigational
Matched Description: … XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sibrotuzumab
Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins …
HPV-16 trojan peptide vaccine
HPV-16 trojan peptide vaccine is an investigational cancer immunotherapy consisting of a novel Trojan peptide complex, composed of human papilloma virus 16 (HPV 16) epitopes, to stimulate antigen-specific CD4 and CD8 T cell responses.
Investigational
Matched Description: … papilloma virus 16 (HPV 16) epitopes, to stimulate antigen-specific CD4 and CD8 T cell responses. ... is an investigational cancer immunotherapy consisting of a novel Trojan peptide complex, composed of human …
ING-1
ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractive target for immunotherapy.
Investigational
Matched Description: … ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton …
AVR118
AVR118 represents a new type of biopolymer chemistry that also possesses novel immunomodulator activity. This non-toxic peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant...
Investigational
Matched Description: … to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human ... This non-toxic peptide-nucleic acid, which to date has shown no indication of human toxicity, appears ... papilloma virus and to dampen aberrant autoimmune-type inflammatory responses. …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Viralym-C
Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]
Investigational
Matched Description: … It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. ... It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection …
MDX-1379
MDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.
Investigational
KB001
KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated patients.
Investigational
Matched Description: … treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and …
MVA-BN-brachyury-TRICOM vaccine
MVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine. It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1...
Investigational
Matched Description: … transcription factor and tumour-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory ... B7-1, ICAM-1 and LFA-3. ... recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human …
Omburtamab
CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours.[A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers. Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous...
Investigational
Matched Description: … CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours ... [A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are …
ADU-S100
ADU-S100 (MIW815) is a synthetic cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING), a receptor crucial to activate the innate (endogenous) immune system. ADU-S100 (MIW815) activates all known human and mouse STINGs, and effectively induces the expression of cytokines and chemokines, leading to a robust and durable...
Investigational
Matched Description: … ADU-S100 (MIW815) activates all known human and mouse STINGs, and effectively induces the expression ... of cytokines and chemokines, leading to a robust and durable antigen-specific T-cell mediated immune …
Matched Salts cas: … 1638750-95-4 …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Matched Salts cas: … 1638750-95-4 …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
LV-SMENP Vaccine
LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of selected viral proteins. This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs).
As of August 2020, this vaccine...
Investigational
Matched Description: … This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs). ... As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
NKG2D-ACE2 CAR-NK Cell
These cells are prepared as universal off-the-shelf CAR-NK cells from cord blood with NKG2D-ACE2 proteins engineered as part of the CARs; the cell secretes IL-15 and GM-CSF. Chimeric antigen receptors (CARs) are artificial receptors consisting of an antibody-derived antigen binding domain and transmembrane and signaling domains from T-cell receptor signalling...
Investigational
Matched Description: … Chimeric antigen receptors (CARs) are artificial receptors consisting of an antibody-derived antigen ... First used with autologous human T cells (CAR-T) as cancer immunotherapies, these receptors are now being ... binding domain and transmembrane and signaling domains from T-cell receptor signalling moieties. …
VPM1002
The bacille Calmette-Guérin (BCG) vaccine protects against severe extrapulmonary forms of tuberculosis (TB) but does not adequately protect against pulmonary TB -- the most prevalent form of TB. This recombinant BCG, VPM1002, has been created in response and investigated for preventing pulmonary TB in newborns and TB recurrence in adults...
Investigational
Matched Description: … Mycobacterial antigen accessing the cytosol also improves antigen presentation. ... As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials ... TB in newborns and TB recurrence in adults through post-exposure immunization. …
COVID19 s-vax loaded autologous dendritic cell vaccine
Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors. These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine.
Dendritic Cells (DCs) are showing potential as natural adjuvants...
Investigational
Matched Description: … boost cell responses; they are considered the most powerful antigen-presenting cells, and are able to ... As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety ... and immunogenicity of the vaccine. …
Displaying drugs 176 - 191 of 191 in total